secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0001808805-24-000070
Event type: earnings
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Q3 net loss $16.4M, cash $221.2M; OpEx flat YoY at $19.1M
------------------------------------------------------------------

- Net loss of $16.4M for Q3 2024, compared to $15.9M loss in Q3 2023.
- Operating expenses $19.1M, flat YoY; personnel cost increase offset by incentive accrual reduction.
- Cash, equivalents, and investments totaled $221.2M as of September 30, 2024.
- CEO notes positive researcher feedback for single-molecule proteome platform, no revenue reported.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/0001808805-24-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880524000070/naut-20241029.htm
  HTML page:      https://secwatch.observer/filing/0001808805-24-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer